Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Compugen Ltd. (CGEN:NASDAQ), powered by AI.
Compugen Ltd. is currently trading at $2.26. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Compugen Ltd. on Alpha Lenz.
Compugen Ltd.'s P/E ratio is -14.2.
“Compugen Ltd. trades at a P/E of -14.2 (undervalued) with modest ROE of -23.6%. 3Y revenue CAGR of 66.8% highlights clear growth momentum.”
Ask for details →Compugen Ltd. is a pioneering biotechnology company focused on the discovery and development of novel therapeutics for cancer immunotherapy. The company employs a unique predictive computational discovery platform that leverages extensive biological data to identify new drug targets and biomarkers, helping to streamline the traditionally complex and lengthy drug development process. As a leader in precision medicine, Compugen Ltd. specializes in immuno-oncology, an advanced field that aims to harness the body's immune system to combat cancer more effectively. The company's innovative approach has positioned it as an influential figure in the biotech industry, collaborating with leading pharmaceutical companies to bring cutting-edge cancer treatments to market. Based in Israel with additional operations in the United States, Compugen Ltd. plays a critical role in advancing healthcare by focusing on precision therapeutics that address the specific needs of patients.
“Compugen Ltd. trades at a P/E of -14.2 (undervalued) with modest ROE of -23.6%. 3Y revenue CAGR of 66.8% highlights clear growth momentum.”
Ask for details →